The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.
* Independent, unbiased, up-to-date - now with esketamine (Spravato)
* Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
* Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine
* New formulations and trade names include: Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Spravato, Sublocade, Zelapar
* Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug
* Potential interactions and side effects summarized in comparison charts
* With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
* Clearly written patient information sheets available for download as printable PDF files
This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.
-------------------------------------------------------------------------------------------
New in this edition:
* Antidepressants chapter includes new section on esketamine (Spravato), recently approved for treatment-resistant depression; also updates to antidepressant use in pregnancy and SPARI drug interactions
* Antipsychotics updates include new section on 5-HT2A inverse agonist antipsychotic (pimavanserin, Nuplazid) and comprehensive revision of augmentation strategies
* Pharmacogenomics chapter fully revised with expanded dose adjustment recommendations
* Chart of agents under investigation for treatment of substance use disorders fully revised, new agents include lofexidine (Lucemyra), Kadian, nortriptyline e-cigarettes
* Unapproved treatments chapter with significant updates, including new sections on adrenergic agents in PTSD (doxazosin), antiflammatory agents in depression (pioglitazone, rosiglitazone, statins), and hormones in schizophrenia (raloxifene)
* Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine
* New formulations and trade names include: Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Spravato, Sublocade, Zelapar